OncoMatch/Clinical Trials/NCT06210971
Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer
Is NCT06210971 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including liposomal irinotecan and Capecitabine for rectal cancer.
Treatment: liposomal irinotecan · Capecitabine — This single-arm trial will explore the efficacy and safety of long-course neoadjuvant chemoradiation with liposomal irinotecan and capecitabine guided by UGT1A1 status in patients with locally advanced rectal cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Colorectal Cancer
Biomarker criteria
Required: UGT1A1 *1*1
UGT1A1 genotype of *1*1
Required: UGT1A1 *1*28
UGT1A1 genotype of *1*28
Disease stage
Required: Stage T3-4NANYM0, T1-2N+M0
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Lab requirements
Blood counts
ANC ≥1.5×10^9/L, Platelet count ≥100×10^9/L, Hemoglobin (Hb) ≥90 g/L
Kidney function
Serum creatinine ≤1.5 × ULN or creatinine clearance ≥60 mL/min
Liver function
Total bilirubin ≤1.5 × ULN, AST and ALT ≤2.5×ULN, Serum albumin ≥3 g/dL
Adequate bone marrow function as evidenced by: Absolute neutrophil count (ANC) ≥1.5×10^9/L, Platelet count ≥100×10^9/L, Hemoglobin (Hb) ≥90 g/L. Adequate hepatic function as evidenced by: Total bilirubin ≤1.5 × ULN, AST and ALT ≤2.5×ULN, Serum albumin ≥3 g/dL. Adequate renal function as evidenced by: Serum creatinine ≤1.5 × ULN or creatinine clearance ≥60 mL/min.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06210971 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require UGT1A1?
Yes, UGT1A1 *1*1 is a required biomarker for enrollment.
Does this trial require UGT1A1?
Yes, UGT1A1 *1*28 is a required biomarker for enrollment.
What disease stage is eligible?
Stage T3-4NANYM0 or T1-2N+M0 is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages